Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF – Get Free Report) was the recipient of a large increase in short interest in the month of October. As of October 30th, there was short interest totaling 82,400 shares, an increase of 41,100.0% from the October 15th total of 200 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ? days.
Shanghai Junshi Biosciences Stock Performance
OTCMKTS:SHJBF opened at C$3.35 on Thursday. Shanghai Junshi Biosciences has a 52-week low of C$2.99 and a 52-week high of C$4.23. The stock’s 50 day moving average price is C$3.35 and its 200 day moving average price is C$3.23.
Shanghai Junshi Biosciences Company Profile
Shanghai Junshi Biosciences is a biopharmaceutical company founded in 2012 and headquartered in Shanghai, China. It develops innovative medicines, with research programs spanning oncology, autoimmune and metabolic diseases, and infectious diseases. The company’s best-known product is toripalimab, an anti-PD-1 antibody marketed in China as Tuoyi and in the United States as Loqtorzi. It is used for certain cancers, including nasopharyngeal carcinoma. Junshi also develops a pipeline of antibody-based and other therapies at different stages of research and clinical development.
Featured Stories
- Five stocks we like better than Shanghai Junshi Biosciences
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
Receive News & Ratings for Shanghai Junshi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shanghai Junshi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
